Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK588745PMID: 36701512
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 197922-42-2
Drug Levels and Effects
Summary of Use during Lactation
Because it is a large protein molecule with a molecular weight of 3752 Da, the amount in milk is likely to be very low. Teduglutide is also poorly absorbed orally so absorption by a breastfed infant is unlikely. Two breastfed infants apparently experienced no adverse effects during maternal use of teduglutide, but no long-term data are available. Until more data are available, teduglutide should be used with careful infant monitoring during breastfeeding.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
One mother used teduglutide during pregnancy and postpartum while breastfeeding. She breastfed her infant (extent not stated) for 6 months. No mention was made of any adverse effects in the infant.[1]
A woman taking teduglutide because of removal of a portion of her gastrointestinal tract became pregnant and delivered a healthy infant. She breastfed her infant and the drug was restarted 1 month after delivery. She breastfed (extent not stated) her infant for another 4 months during treatment. The infant experienced no side effects during breastfeeding.[2]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Gentilini MV, Doeyo M, Ortega M, et al. Successful pregnancy in a patient with short bowel syndrome after surgical rehabilitation and sGLP-2 treatment: Novel report on endogenous GLP-2 levels at delivery and during breastfeeding. Therap Adv Gastroenterol 2022;15:17562848221129787. [PMC free article: PMC9706046] [PubMed: 36458051]
- 2.
- Lillienau J, Nilsson E, Vulcan A, Nilsson A. 90: Use of teduglutide during breast-feeding after pregnancy in a patient with severe intestinal failure. Transplantation 2023;107:53. doi:10.1097/01.tp.0000945816.46782.83 [CrossRef]
Substance Identification
Substance Name
Teduglutide
CAS Registry Number
197922-42-2
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PMCPubMed Central citations
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.[Gut. 2005]Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, Gregory J, Tappenden KA, Holst J, Mortensen PB. Gut. 2005 Sep; 54(9):1224-31.
- Review Teduglutide in intestinal adaptation and repair: light at the end of the tunnel.[Expert Opin Investig Drugs. 2008]Review Teduglutide in intestinal adaptation and repair: light at the end of the tunnel.Mardini HE, de Villiers WJ. Expert Opin Investig Drugs. 2008 Jun; 17(6):945-51.
- Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.[J Pediatr Gastroenterol Nutr. ...]Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.Thymann T, Stoll B, Mecklenburg L, Burrin DG, Vegge A, Qvist N, Eriksen T, Jeppesen PB, Sangild PT. J Pediatr Gastroenterol Nutr. 2014 Jun; 58(6):694-702.
- Review Teduglutide for the treatment of short bowel syndrome.[Ann Pharmacother. 2006]Review Teduglutide for the treatment of short bowel syndrome.Ferrone M, Scolapio JS. Ann Pharmacother. 2006 Jun; 40(6):1105-9. Epub 2006 May 16.
- Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.[J Pharmacol Exp Ther. 2020]Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.Hargrove DM, Alagarsamy S, Croston G, Laporte R, Qi S, Srinivasan K, Sueiras-Diaz J, Wiśniewski K, Hartwig J, Lu M, et al. J Pharmacol Exp Ther. 2020 May; 373(2):193-203. Epub 2020 Feb 19.
- Teduglutide - Drugs and Lactation Database (LactMed®)Teduglutide - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...